Form D · Pharmaceuticals
LIMERICK BIOPHARMA INC
San Francisco, CA · CIK 0001358877
Offering snapshot reported Jan 30, 2012 · SEC filing
- Reported sold
- $480K Offering amount: $480K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 5, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 30, 2012 | Initial | $480,000 | No comparison | 5 | SEC filing |
| Jul 26, 2011 | Amendment | $9,939,415 | $3,050,000vs Mar 10, 2011 | 13 | SEC filing |
| Mar 10, 2011 | Amendment | $6,889,415 | $3,304,415vs Dec 20, 2010 | 13 | SEC filing |
| Dec 20, 2010 | Initial | $3,585,000 | No comparison | 13 | SEC filing |
| Aug 20, 2009 | Amendment | $15,380,000 | $380,000vs Jul 16, 2009 | 17 | SEC filing |
| Jul 16, 2009 | Initial | $15,000,000 | No comparison | 7 | SEC filing |
| Jun 5, 2009 | Initial | $1,500,000 | No comparison | 5 | SEC filing |
| Apr 30, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 11, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 28, 2006 | Paper | Not reported | No comparison | Not reported |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-172591
Secured Convertible Promissory Notes (including (i) the shares of Preferred Stock issuable upon conversion of the Notes and (ii) the shares of Common Stock issuable upon conversion of the Preferred Stock).
Source: Form D, filed Jan 30, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kristina Burow | Director |
| Steve Dow | Director |
| Stephen M. Dow | Director |
| Corey Goodman | Director |
| Ving Lee | Executive |
| Scott Minick | Director |
| Asha Rajagopal | Executive |
| Wendye Robbins | Director, Executive |
| Chad Waite | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
181 28 Th Avenue
San Francisco, CA, 94121
San Francisco, CA, 94121